NCT03006029View on ClinicalTrials.gov

Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 8, 2017

Primary Completion Date

May 14, 2019

Study Completion Date

August 13, 2019

Conditions
Solid Tumors
Interventions
DRUG

TAB08

The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.

Trial Locations (1)

Unknown

"GBU Ryazanskoy Oblasti Oblastnoy klinicheckiy oncologicheskiy dispanser", Ryazan

All Listed Sponsors
lead

Theramab LLC

INDUSTRY

NCT03006029 - Dose Escalation Study of TAB08 in Patients With Advanced Solid Neoplasms | Biotech Hunter | Biotech Hunter